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Background: Pancreatic ductal adenocarcinoma (PDAC) is distinguished by rapid dissemination. Thus, genetic and/
or epigenetic deregulation of metastasis suppressor genes (MSG) is a likely event during early pancreatic
carcinogenesis and a potential diagnostic marker for the disease. We investigated 9 known MSGs for their role in
the dissemination of PDAC and examined their promoters for methylation and its use in PDAC detection.
Methods: MRNA expression of 9 MSGs was determined in 18 PDAC cell lines by quantitative RT-PCR and promoter
methylation was analyzed by Methylation Specific PCR and validated by Bisulfite Sequencing PCR. These data were
compared to the cell lines’ in vivo metastatic and invasive potential that had been previously established. Statistical
analysis was performed with SPSS 20 using 2-tailed Spearman’s correlation with P < 0.05 being considered
significant.
Results: Complete downregulation of MSG-mRNA expression in PDAC cell lines vs. normal pancreatic RNA occurred
in only 1 of 9 investigated genes. 3 MSGs (CDH1, TIMP3 and KiSS-1) were significantly methylated. Methylation only
correlated to loss of mRNA expression in CDH1 (P < 0.05). Bisulfite Sequencing PCR showed distinct methylation
patterns, termed constant and variable methylation, which could distinguish methylation-regulated from non
methylation-regulated genes. Higher MSG mRNA-expression did not correlate to less aggressive PDAC-phenotypes
(P > 0.14).
Conclusions: Genes with metastasis suppressing functions in other tumor entities did not show evidence of
assuming the same role in PDAC. Inactivation of MSGs by promoter methylation was an infrequent event and
unsuitable as a diagnostic marker of PDAC. A distinct methylation pattern was identified, that resulted in reduced
mRNA expression in all cases. Thus, constant methylation patterns could predict regulatory significance of a
promoter’s methylation prior to expression analysis and hence present an additional tool during target gene
selection.
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Pancreatic ductal adenocarcinoma (PDAC) is a highly
aggressive malignancy with a dismal 5-year survival rate
of less than 5%, a median survival of 6 months and a
mortality to incidence ratio of 0.98 [1,2]. While surgical
intervention represents the only curative treatment op-
tion, more than 80% of patients with PDAC present with
irresectable disease [3,4]. Yet even after surgery, 5-year
survival in specialized centers reaches no more than 25%
with (neo)adjuvant treatment and remains below 15%
without it [5,6]. Existing strategies seem to be exhausted
and novel markers as well as new therapeutic targets are
needed to both move forward the time of diagnosis and
increase treatment efficacy.
Genetic alterations to factors and pathways underlying
pancreatic ductal carcinogenesis, such as KRAS, TP53,
SMAD4 and Hedgehog are under close investigation [7].
However, beside genetic alterations, epigenetic mecha-
nisms for gene inactivation, such as transcriptional silen-
cing by promoter methylation, seem to be important in
the pathogenesis of PDAC [8]. Recent studies have shown
that aberrant methylation of CpG-islands is a common
mechanism associated with the silencing of tumor-
suppressor and cancer-related genes in pancreatic cancers
[9], among them BRCA1, APC, and p16INK4a [10-12].
These aberrant methylation patterns and the resulting
changes in gene expression may over the long term be
drawn upon as therapeutic targets. A more tangible use
however may be their exploit as biomarkers; these would
ideally enable earlier diagnosis or even screening for pan-
creatic cancer. Presently, the disease is mostly diagnosed
by the onset of clinical symptoms which occur at later
stages, when a curative approach, i.e. resection, is mostly
no longer possible. Moving forward the time of diagnosis
would thus increase survival through identification at
more treatable disease stages [13,14]. As a consequence,
biological changes used for the detection of PDAC should
ideally be present early on in pancreatic carcinogenesis
and precancerous lesions. Prevalence of low-level aberrant
methylation has indeed been detected in well-defined pan-
creatic intraductal neoplasia (PanIN) lesions and over-
expression of DNA methyltransferase 1 has been found in
precancerous conditions and it increased with disease pro-
gression [15]. Detection of aberrant methylation in body
fluids such as serum, urine, pancreatic juice or sputum
could also be a useful marker for PDAC [16]. For example,
analysis of NPTX2 [17,18], RASSF1A [19], cyclin D2 [20],
ppENK and pi6 [21] hypermethylation may enable the cre-
ation of a highly sensitive and less invasive panel of
markers for pancreatic cancer. These findings raise hopes
that early markers of PDAC may be developed based on
aberrant methylation patterns.
Due to the disease’s rapid progression and early metas-
tasis formation, metastasis suppressor genes (MSGs)may be deregulated early during pancreatic carcinogen-
esis. Clinically and experimentally, primary tumor devel-
opment and metastasis formation are distinct processes.
Metastasis suppressors are defined as inhibitors of me-
tastasis at any step of the metastatic cascade without
interfering with primary tumor growth [22]. The discov-
ery of these endogenous molecules that exclusively in-
hibit metastasis and the understanding of their actions
suggest that metastasis is an amenable therapeutic tar-
get. However, only few of the currently known MSGs
have been investigated in pancreatic cancer so far. In the
present study, we selected a comprehensive panel of
MSGs based on review of metastasis suppressors by
Shevde and Welch [23].
Taken together, our review of the current literature re-
vealed 1) earlier diagnosis of PDAC would increase sur-
vival, 2) hypermethylation occurs early during pancreatic
carcinogenesis and 3) metastasis suppressor genes have
not been sufficiently researched in this context. Accord-
ingly, we investigated a number of known MSGs for
their influence on PDAC dissemination and the methyla-
tion status of their promoter region In order to identify
possible PDAC biomarker candidates.
Methods
Ethics statement
All animal experiments were conducted in accordance
with the national guidelines for the care and use of la-
boratory animals, and the experimental protocol was ap-
proved by the state agency for animal welfare of North
Rhine-Westphalia (LANUV; NRW, Germany).
Genes of interest
Analyses were carried out for 9 known MSGs, as
reviewed by Shevde and Welch [23]: BRMS1, CD82,
CDH1, KiSS-1, MAP2K4, MED23, NDRG1, TIMP3 and
TXNIP.
Cell lines
18 human PDAC cell lines were analyzed in vitro. All
cell lines were obtained from American Type Culture
Collection, except A818, PT45, HPAF2 and MiaPaCa2
which were originally obtained from American Type
Culture Collection and provided by H. Kalthoff, Depart-
ment of Surgery, University Hospital Kiel, Germany and
H. Hotz, Department of Surgery, Charite CBF, University
Hospital Berlin, Germany. Cells were maintained in
recommended growth media, and all media were
supplemented with 10% heat inactivated fetal bovine
serum (Gibco / Invitrogen, Karlsruhe, Germany) and
were mycoplasma negative. For culturing, they were in-
cubated at 37°C in humidified air with 5% or 10% CO2.
The medium was replaced twice a week, and cells were
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0.1% trypsin.
Animal model and biological classification of cell lines
An orthotopic implantation tumor model using four-
week-old male nude mice (Crl:NU/NU-nuBR) had been
carried out previously [24]. In brief, four-week-old male
nude mice (Crl:NU/NU-nuBR) were injected subcutane-
ously with each human PDAC cell line. These mice were
euthanized after 3 to 4 weeks and the donor tumors col-
lected, fragments of which were inserted orthotopically
into another mouse’s pancreatic parenchyma (n = 10
mice per cell line). HS766T and PL45 failed to form tu-
mors in donor mice and thus were excluded from
in vivo, but not from in vitro analysis. After a growth
phase of 12 weeks, primary tumor volume, local infiltra-
tion and patterns of local and systemic metastases were
assessed systematically as previously described [25]. The
results were compiled into a score each for metastasis
and invasion.
Nucleic acid preparation
DNA and RNA extraction from cell lines was performed
using the DNeasy Blood & Tissue and the RNeasy Mini
Kit from Qiagen (Hildesheim, Germany) according to
the manufacturer’s specifications. A total RNA prepar-
ation from human pancreas was acquired from Applied
Biosystems (Darmstadt, Germany). RNA samples were
stored at −80°C. CDNA was generated using the High
Capacity cDNA Reverse Transcription Kit from Applied
Biosystems according to the manufacturer’s specifica-
tions. CDNA was stored at −20°C. Purity and concentra-
tion of nucleic acids were measured in a biophotometer
(Eppendorf, Hamburg, Germany).
Bisulfite modification
Bisulfite modification of DNA was performed with
EpiTect Bisulfite Kits from Qiagen according to the
manufacturer’s specifications. Obtained products were
stored at −20°C.
Methylation assays
Methylation specific PCR (MSP) and Bisulfite sequen-
cing PCR (BSP) were carried out as previously described
for in vitro cell lines [26]. BSP results were analyzed with
the Beckman Coulter CEQ 8800 Genetic Analysis Sys-
tem software v9.0 using C- to T-peak ratios to define a
CpG-dinucleotide as methylated, unmethylated or het-
erogeneously methylated for each CpG-dinucleotide.
Point values were assigned to each CpG-dinucleotide
according to its methylation status as follows: un-
methylated: 0; heterogeneously methylated: 1; methyl-
ated: 2. A methylation-score was calculated for each
gene in each cell line by using the average point value ofall investigated CpG-dinucleotides for that gene, result-
ing in values from 0.0 (completely unmethylated) to 2.0
(completely methylated).
Quantitative reverse transcriptase-PCR
Quantitative reverse transcriptase-PCR (qRT-PCR) had
been previously performed for in vitro cell lines [26].
Calculations were carried out using the qBase algorithm
in Microsoft Excel using the 2-ΔΔCT Method with PPIB
and HPRT1 as reference genes [27].
Statistical analysis
Statistical analysis was performed using 2-tailed
Spearman’s correlation. 95% confidence intervals were
calculated and P < 0.05 was considered significant. SPSS
20.0 (SPSS Inc., Chicago, IL, USA) was used for these
calculations.
Results
Animal model: tumor biology of the PDAC cell lines
In vivo metastatic potential had been previously investi-
gated for 16 PDAC cell lines and quantified by a
metastasis- and invasion-score [24]. In brief, the scores
were calculated by crediting one point for every local in-
filtration, every colonized organ, and for multiple meta-
static lesions per organ. Score values represent mean
sums of the obtained credit points for all mice in a
group.
Metastasis suppressor gene mRNA expression
We investigated the expression of 9 MSGs by qRT-PCR
for 18 PDAC cell lines and normal human pancreatic
RNA. Gene selection was performed at the beginning of
the investigation and reflects the known MSGs at that
time. In 6/9 genes (BRMS1, CD82, CDH1, MED23,
NDRG1 and TXNIP) and both reference genes (HPRT1,
PPIB) mRNA was detected in all samples. Of the
remaining 3 genes, KiSS-1 was detected in all cell lines
except MiaPaCa2; MAP2K4 was detected in all cell lines
except A818, MPanc 96, PaTu 8902, PaTu 8988S and
PaTu 8988 T; TIMP3 was detected in all cell lines except
A818, MiaPaCa2, PaTu 8902 and PaTu 8988 T.
Of note: Isolation of in vivo samples of sufficient qual-
ity (RIN > 7.0; tumor cells >80% in microscopic analysis)
was not possible. The underlying reasons are presented
in the discussion section.MAP2K4, TIMP3 and TXNIP
were downregulated in most PDAC cell lines while
BRMS1 and KiSS-1 showed predominant upregulation
vs. normal pancreatic RNA (Figure 1 and [26]).
Methylation specific PCR
MSP analysis of CpG-islands in the promoter region of
the investigated genes showed 3 patterns. 1) and 2): Only
one band was found per MSP: either the PCR with the
Figure 1 Metastasis suppressor gene mRNA expression. Legend: MRNA expression (qRT-PCR) of metastasis suppressor genes in PDAC cell
lines and normal pancreatic RNA as previously determined by our group [26]. Normal pancreatic RNA is highlighted, demonstrating that
downregulation of metastasis suppressor genes in PDAC cell lines vs. normal RNA was not a uniform occurrence.
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PCR with the unmethylation-specific primer did not or
vice versa. 3) Both PCRs from the same MSP showed
bands simultaneously. The results were therefore classi-
fied as homogenously methylated, homogenously un-
methylated or heterogeneously methylated (Figure 2A).
No gene was methylated in all cell lines while several
genes were unmethylated across all cell lines (Figure 2B).
Gel pictures are provided in Additional file 1.Bisulfite sequencing PCR and direct sequencing
Three types of signals were present at the CpG-sites: 1) A
T-peak and no C-peak; classified as an unmethylated
CpG-dinucleotide 2) A C-peak and no T-peak; classified
as a methylated CpG-dinucleotide 3) Superimposing C-
and T-peaks; classified as heterogeneously methylated
CpG-dinucleotide. 5 of the 9 investigated genes (CD82,
MAP2K4, MED23, NDRG1, TXNIP) showed no methyla-
tion throughout the entire sequenced region (Figure 3).
Figure 2 Methylation specific PCR. Legend: A) Example of a
methylation specific PCR: KiSS-1. Samples are noted above the image
and primer specificity is declared as U, specific for unmethylated
template, or M, specific for methylated template. 3 distinct signal
patterns were observed: either only the U- or the M-band was
present, or both bands were present. Cell lines were thus identified
as unmethylated (e.g. MPanc96), methylated (e.g. PaTu8988S) or
heterogeneously methylated (e.g. CAPAN2). B) MSP-analysis for all
cell lines and genes. Each column represents a gene and its
methylation status in a cell line is indicated by partially filled circles.
Methylation status for each cell line was determined as illustrated in
Figure 3A for the example for KiSS-1. *different results for MSP- vs.
BSP-analysis (compare to Figure 3).
Figure 3 Overview of bisulfite sequencing methylation scores.
Legend: Increasingly colored in circles represent methylation score
ranges from bisulfite sequencing. Residual methylation was present
in BRMS1, which however still translated into an overall methylation
score of <0.4. Detailed methylation maps are provided in Figure 4.
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TIMP3 showed significant methylation, with differing
methylation patterns and intensities (Figure 4).
Correlation between MSP and BSP-direct sequencing
MSP-status and the BSP methylation-score were highly
correlated in the methylated genes (P < 0.005, except
TIMP3: P < 0.05). However, differing results betweenMSP and BSP-direct sequencing were discovered for 2
cell lines in TIMP3 and 11 cell lines in KiSS-1. In all of
these instances, BSP-direct sequencing was more sensi-
tive to methylation than MSP (Figure 2B and Figure 3).
The unmethylated genes were identified as such by both
methods with only BRMS1 showing minor methylation
in BSP-direct sequencing.
Overall, BSP proved more sensitive to methylation
than MSP, delivering an explanation for the only slightly
differing results in KiSS-1. In TIMP3 however, greater
discrepancies were encountered, suggesting the pos-
sibility of differential methylation patterns within the
promoter island as the BSP-sequenced region did not in-
clude the region in which the MSP primers were
situated.
Methylation patterns
We identified two distinct methylation patterns in the four
genes with significant promoter methylation. The first pat-
tern was dubbed variable methylation: In BRMS-1, KiSS-1
and TIMP3, volatility of methylation was high with paral-
lel occurrence of methylated, heterogeneously methylated
and unmethylated CpGs at a single methylation site
Figure 4 Methylation volatility. Legend: Each box represents one sequenced CpG in 5′ to 3′ order whose methylation status is indicated by
coloration. Some cell lines have uniform methylation patterns throughout the entire investigated region of a gene (e.g. CDH1 in MiaPaCa2:
constant methylation pattern), while a more inconsistent pattern is present in other cases (e.g. PL45 in TIMP3: variable methylation pattern).
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termed constant methylation: CDH1 was only methylated
in 2/18 (11%) cell lines. In contrast to the methylation-
variability observed in the first group, the CDH1 promoter
had a constant methylation pattern for single cell lines:
the cell lines displayed either uniformly high or uniformly
low methylation across the entire sequenced promoter re-
gion with low methylation volatility. Promoter methylation
and mRNA expression data from 2 additional metastasis
suppressors, AKAP12 and SERPINB5, were included for
methylation pattern analysis. Our group has previously in-
vestigated these genes and identified a stable methylation
pattern for the SERPINB5 promoter while AKAP12
displayed variable methylation [26]. Figure 5A is a graphic
representation of the differences in overall methylation in-
tensity and variability of methylation intensity. Differences
in the standard deviation of the methylation scores was
used as a mathematical basis for the definition of variable
or constant methylation patterns: methylation score stand-
ard deviation of ≤0.09 was defined as constant methyla-
tion, and >0.09 as variable methylation (Figure 5B).
In summary, we identified three types of promoter
methylation: 1) Genes with completely unmethylated
promoters 2) Genes whose promoters were methylated
in most cell lines and that showed highly variable methy-
lation intensity (methylation score standard deviation
>0.09), dubbed variable methylation. 3) Gene promotersthat were methylated in few cell lines and with constant
methylation intensity (methylation score standard devi-
ation ≤0.09), dubbed constant methylation.
Correlation between promoter methylation and loss of
mRNA expression
The expression levels of the 4 methylated genes were in-
vestigated for differential mRNA expression in correl-
ation to their promoter methylation status. The priorly
investigated genes, SERPINB5 (constant methylation
pattern) and AKAP12 (variable methylation pattern)
were included for this analysis. In the genes with con-
stant methylation (CDH1 and SERPINB5) the signifi-
cantly methylated cell lines had the lowest mRNA
expression across all cell lines. For the variably methyl-
ated genes (AKAP12, BRMS1, KiSS-1 and TIMP3), no
significant correlations between methylation-score and
mRNA expression were detected. Thus, constant methy-
lation patterns exerted influence on mRNA expression
in all cases, while all instances of variable methylation pat-
terns had no influence on mRNA expression (Table 1).
Correlation between metastasis suppressor gene mRNA
expression and tumor biology
No significant correlations between MSG mRNA expres-
sion and tumor biology were detected. Both invasion
and metastasis scores were not correlated to expression
Figure 5 Methylation volatility. Legend: A) Each row represents the sequenced CpG sites of one gene with each bar standing for one CpG-site
in 5′ to 3′ direction. Bar height denotes the average methylation-score of that CpG-site across all cell lines. Variably methylated genes (AKAP12,
BRMS1, TIMP3, KiSS-1) showed generally higher methylation with greater volatility than genes with constant methylation (CDH1, SERPINB5). B) The
observation in A is quantified by differing levels of methylation volatility: genes with constant methylation had lower standard deviation of
methylation levels than those with variable methylation.
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(Additional file 2: Table S1).
Discussion
Although aberrant methylation is a frequent epigenetic
event for a number of genes in pancreatic cancer, in the
present study, promoter methylation was present in only
4 of 9 investigated genes and only resulted in reduced
mRNA expression one of them, CDH1.
For further analysis of methylation levels, we included
2 previously investigated, methylated genes: AKAP12
and SERPINB5, increasing the number of methylated
genes to 6. For this group of genes we found 2 distinct
and mutually exclusive types of methylation, either “con-
stant” or “variable” methylation. Variably methylated
genes showed considerable methylation volatility for sin-
gle CpG sites with methylation levels changing from
completely unmethylated to completely methylated sev-
eral times throughout the sequenced promoter region.Table 1 Correlation of methylation patterns to mRNA express
Constant methylation
CDH1 SERPIN
Methylation score vs. mRNA expression P < 0.05 P < 0.0
Legend: Constant methylation patterns are correlated to loss of mRNA expression, wThe genes in this group were AKAP12, BRMS1, KiSS-1
and TIMP3 -- genes for which there was no correlation
between promoter methylation and mRNA expression.
Thus, variable methylation, even though often occurring
at high levels, did not translate into loss of mRNA ex-
pression. This suggests that variable methylation patterns
could be a by-product of tumor dedifferentiation and pos-
sibly DNMT-1 (DNA methyltransferase 1) overexpression
without regulatory links to mRNA-expression. DNMT1
protein expression has been reported to increase progres-
sively during the stages of pancreatic carcinogenesis and
was found to be associated with tumor aggressiveness,
suggesting that protein overexpression of DNMT1 and en-
suing hypermethylation may be involved in multistage
pancreatic carcinogenesis -- even though it may not trans-
late into loss of mRNA expression [15]. In contrast, for
SERPINB5 and CDH1, the genes with constant methylation
patterns, the methylated cell lines showed the lowest mRNA
expression across all investigated samples, correlating thision
Variable methylation
B5 AKAP12 BRMS1 KiSS-1 TIMP3
5 n.s. n.s. n.s. n.s.
hile variable methylation patterns are not.
Mardin et al. BMC Cancer 2013, 13:264 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/264pattern of methylation to loss of mRNA expression. These
observations suggest that the functional relevance of pro-
moter methylation can be predicted even before carrying
out quantitative reverse transcriptase PCR, based only on
methylation patterns. While confirmation by qRT-PCR
will still be necessary, target selection could be made more
efficient through the pre-selection of genes of interest
according to their methylation pattern.
Surprisingly, overexpression of some investigated
MSGs was found in many tumor cell lines compared to
normal pancreatic RNA. For example, BRMS1 demon-
strated nearly uniform upregulation in the PDAC cell
lines (94%, 17/18 cell lines). This gene was first de-
scribed in breast cancer and was more recently found to
decrease metastatic potential in that tumor entity by
upregulating microRNA miR-146 [28]. While we do not
know whether miR-146 induction by BRMS1 also occurs
in PDAC, it is known that miR-146 is overexpressed in
pancreatic cancer vs. both normal pancreas and pancrea-
titis, suggesting that miR-146 has an oncogenic role in
pancreatic cancer [29]. This corresponds to our present
findings of nearly uniform upregulation of BRMS1 in
PDAC vs. normal tissue. Further investigation of the
BRMS1 / miR-146 axis in PDAC appears to be warranted.
We encountered substantial difficulties regarding
mRNA expression analysis from in vivo tissues: The re-
covery of mRNA samples of sufficient quality (RIN > 7.0;
tumor cells >80% in microscopic analysis) was not pos-
sible due to 2 main reasons: 1) The orthotopic tumor
specimens decayed too quickly, likely due to auto-
digestion before complete permeating of the RNAse in-
activating agent, resulting in insufficient RIN values
<7.0. 2) The metastases were simply too small for recov-
ery of sufficient sample volume. In addition, it was not
possible to control these samples for contamination by
normal cells without destroying the sample. Thus, we
proceeded without these analyses as they were technic-
ally unfeasible.
None of the investigated genes showed any correlation
to the metastatic or infiltrative potential of 16 PDAC cell
lines in vivo. Instead, some were significantly up-
regulated in the PDAC cell lines vs. normal pancreatic
RNA. The present results suggest that most known me-
tastasis suppressor genes do not assume their ascribed
roles in PDAC and that some metastasis suppressors
even undergo overexpression in this tumor entity. Fur-
ther, promoter methylation does not seem to be a prom-
inent mechanism of loss of expression for metastasis
suppressor genes in PDAC as most genes’ promoter
islands showed no methylation at all. Even when methy-
lation did occur, it did not result in loss of mRNA in
most cases. Thus, assays for metastasis suppressor gene
promoter methylation do not appear to be suitable tools
for the detection of PDAC. However, when methylationdid induce loss of mRNA expression, a distinct methyla-
tion pattern was observed in each case, termed constant
methylation. To our knowledge, methylation patterns
have not yet been correlated to translation into loss of
mRNA expression. Yet methylation patterns may indeed
be able to predict whether or not loss of expression oc-
curs when methylation is present. After a first global
methylation analysis, information on methylation pat-
terns could help to select genes for further, i.e. func-
tional, analysis. Detailed knowledge of epigenetic
alterations and associated molecular mechanisms during
pancreatic tumorigenesis and metastasis will broaden
the biological understanding of the disease and help de-
vise novel targets for earlier diagnosis and increasingly
effective therapies.Conclusions
In summary, our results suggest that metastasis suppres-
sor genes may play different roles in PDAC compared to
other tumor entities, a hypothesis that must be con-
firmed by in depth analysis of single genes. In addition,
we describe promoter methylation patterns that were
correlated to functional relevance: Patterns of constant
promoter methylation appear to predict methylation-
associated control of gene expression.Additional files
Additional file 1: MSP Gels.
Additional file 2: Table S1. Correlation of metastasis suppressor
expression to tumor biology. Legend: No significant correlations between
metastasis suppressor gene expression and in vivo tumor biology were
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